Get startedLog in
    Picture of BLS Pharmaceuticals logo

    BXNDA — BLS Pharmaceuticals News Story

    0.000.00%
    au flag iconLast trade - 00:00
    HealthcareHighly SpeculativeSmall CapHigh Flyer
    All News

    Brief: Bioxyne Reports Full Year FY2026 Revenue Guidance Of A$65 Million - A$75 Million

    Picture of BLS Pharmaceuticals logoBLS Pharmaceuticals
    29/08/2025 03:50
    Aug 29 (Reuters) - Bioxyne Ltd BXN.AX:

FULL YEAR FY2026 REVENUE GUIDANCE OF A$65 MILLION - A$75 MILLION

FULL YEAR FY2026 EBITDA GUIDANCE OF A$11.5 MILLION - A$13.5 MILLION

Further company coverage: BXN.AX

 ((Reuters.Briefs@thomsonreuters.com;))

    Recent news on BLS Pharmaceuticals

    See all news